RT Journal Article
SR Electronic
T1 Randomized placebo-controlled trials of remdesivir in severe COVID-19 patients: A Systematic Review and Meta-analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.21.20179200
DO 10.1101/2020.08.21.20179200
A1 Sarfraz, Azza
A1 Sarfraz, Zouina
A1 Sanchez-Gonalez, Marcos A.
A1 Michel, Jack
A1 Michel, George
A1 Frontela, Odalys
A1 Posada, Jorge
A1 Cardona, Jose
A1 Angueira, Eugonia
YR 2020
UL http://medrxiv.org/content/early/2020/08/24/2020.08.21.20179200.abstract
AB Background The first cases of the coronavirus disease 2019 (COVID-19) were reported in Wuhan, China. No antiviral treatment options are currently available with proven clinical efficacy. However, preliminary findings from phase III trials suggest that remdesivir is an effective and safe treatment option for COVID-19 patients with severe disease.Objective The aim of the present meta-analysis is to investigate whether remdesivir is effective for treating COVID-19 including reduced in-hospital adverse events, oxygen support, and mortality rates.Methods Using PRISMA reporting guidelines, a review was conducted from January 1 2020 until 6 August 2020 with MeSH terms including COVID-19, coronavirus, SARS-CoV-2, COVID, remdesivir, adenosine nucleoside triphosphate analog, Veklury using Medline, Scopus, and CINAHL Plus. A modified Delphi process was used to include the studies and ensure that the objectives were addressed (Appendix A). Using dichotomous data for select values, the unadjusted odds ratios (ORs) were calculated applying Mantel Haenszel (M-H) random-effects method in Review Manager 5.4.Results Randomized controlled trials pooled in 2,429 participants with 41.6% (n = 1011) in the remdesivir group and 58.4% (n = 1,418) in the placebo group. The placebo group had a higher risk of mortality as compared to the intervention group with significant odds ratio (OR = 0.61) (95% confidence interval of 0.45–0.83; P = 0.001). There was moderate heterogeneity among the studies.Conclusions Our findings suggest that remdesivir extends clinical benefits by reducing mortality, adverse events and oxygen support in moderate to severely ill COVID-19 patients. Concerted efforts and further randomized placebo-controlled trials are warranted to examine the potency of anti-viral drugs and immune-pathological host responses contributing to severity of COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was received for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Division of Clinical & Translational Research at Larkin Community Hospital was the oversight body that provided approval for the research.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are openly available in Medline or journal sites including the Lancet, New England Journal of Medicine with 10.1093/cid/ciaa1041; 10.1056/NEJMoa2007764; 10.1016/S0140-6736(20)31022-9. https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1041/5876045#:~:text=In%20this%20comparative%20analysis%2C%20by,patients%20with%20severe%20COVID%2D19. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31022-9/fulltext